Over the past 12–18 months the PCR Mycoplasma Detection Kit market has accelerated through strategic collaborations, technology roll‑outs, and regulatory adjustments that reshape the competitive landscape. In March 2024, Thermo Fisher partnered with BioMérieux to integrate BioMérieux’s proprietary MycoAlert™ assay into a high‑throughput PCR platform, promising a 30 % reduction in turnaround time for cell‑culture testing. Meanwhile, Roche’s acquisition of UK‑based MycoDetect Ltd. in July 2023 expanded its portfolio with a multiplex‑PCR kit capable of detecting 12 Mycoplasma species in a single reaction, positioning Roche for broader biopharma adoption. Early‑2024 saw the launch of Qiagen’s fully automated, cloud‑connected kit that leverages digital PCR for sub‑10‑copy sensitivity, addressing the growing demand for trace‑level monitoring in advanced therapy medicinal products. On the regulatory front, the European Medicines Agency issued updated guidance in February 2024, mandating routine Mycoplasma screening for all ATMPs, which is expected to boost demand. Finally, a $45 million Series B round secured by a Chinese start‑up, MycoSense, will fund a new manufacturing facility in Shanghai, increasing regional supply capacity. These moves illustrate the PCR Mycoplasma Detection Kit industry trends shaping the next growth phase.
